logo

For the Inventor, By the Inventor

Brussels, Belgium

Pierre Van Den Bruggen

This inventor holds 5 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2000-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Van Den Bruggen. Retrieved from https://idiyas.com/inventor/pierre-van-den-bruggen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 80.0

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:

goldMedal5 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents

Years Active: 2000-2009

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7495074 - Isolated proteins MAGE-4 and MAGE-41 (2009-02-24),
2. 6599699 - Methods for diagnosing a disorder by assaying for MAGE-3 (2003-07-29),
3. 6565857 - Methods for treating a disorder by using Mage-3 or Mage-3 related materials (2003-05-20),
4. 6552180 - Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereof (2003-04-22),
5. 6025474 - Isolated nucleic acid molecules coding for tumor rejection antigen (2000-02-15),

Title: **Innovative Contributions of Pierre Van Den Bruggen**

Introduction

Pierre Van Den Bruggen is a prominent inventor based in Brussels, Belgium. With a total of five patents to his name, he has made significant strides in the field of cancer research, particularly in the area of tumor rejection antigens. His innovative work has been influential in developing therapeutic and diagnostic applications in oncology.

Latest Patents

Van Den Bruggen's latest patents focus on isolated proteins MAGE-4 and MAGE-41. These inventions relate to nucleic acid molecules that code for the tumor rejection antigen precursor MAGE-3. The patents also disclose various vectors, cell lines, and additional components that utilize these nucleic acid molecules. Furthermore, the inventions include methodologies for diagnosing disorders through assays that detect MAGE-3, along with therapeutic and diagnostic uses in clinical contexts.

Career Highlights

Pierre Van Den Bruggen is currently affiliated with the Ludwig Institute for Cancer Research Limited, where he leverages his expertise to advance cancer research. His contributions have significantly impacted the understanding of tumor dynamics and patient treatment strategies. Over the years, he has been instrumental in the progression of scientific knowledge through his inventive spirit.

Collaborations

In his research endeavors, Van Den Bruggen has collaborated with numerous esteemed colleagues, including Thierry R. Boon-Falleur and Benoit Van Den Eynde. These collaborations have fostered innovation and provided diverse perspectives in tackling complex challenges within the realm of cancer research.

Conclusion

Pierre Van Den Bruggen is a key figure in the innovative landscape of cancer research. His patented inventions continue to pave the way for future breakthroughs, enhancing therapeutic possibilities and improving diagnostic methods for patients worldwide. Through his dedication and collaborative efforts, Van Den Bruggen exemplifies the spirit of innovation that drives advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…